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Amplification of DHFR gene in CHO cells by selection
of MTx has been widely applied to the establishment of
stable cell lines that efficiently produce recombinant
protein pharmaceuticals. However, the DHFR/MTx
technology was highly time-and labor-consuming. On
the other hand, we had found that a plasmid bearing a
mammalian replication initiation region (IR) and a
matrix attachment region (MAR) initiates gene amplifi-
cation in mammalian cells, and it quite efficiently gener-
ate the chromosomal HSR and/or the
extrachromosomal DMs [1,2]. This is a completely origi-
nal technology of gene amplification, and we have
revealed the mechanism why and how such plasmid
may mimic gene amplification [2,3]. Now, we aimed to
adopt this technology to the industrial production of
recombinant protein pharmaceuticals.
We constructed plasmids with or without IR/MAR,
with several promoters for drug resistant gene, antibody
gene or Fc receptor gene, and with various orientations
of these elements. The plasmid DNA with several physi-
cal structures were transfected to human COLO 320DM
or hamster CHO DG44 cells, with or without another
DNA. The transformed cells were selected by various
conditions. The polyclonal transformants or the cloned
cells were evaluated by the protein production (ELISA),
as well as by the structure of amplified region (FISH).
As a result, the usage of IR/MAR technology enabled
us to obtain cells, in which the introduced genes were
amplified to a few hundreds to thousands copies per
cells as DMs or HSR of various size and shape (Figure
1), which depended both on the vector constructs and
the host cell lines. Such stable cells with amplified genes
c o u l db eo b t a i n e dw i t h i no n em o n t h ,a n dt h ep r o t e i n
production was increased more than a hundred-fold
compared with the case without IR/MAR. A cell clone
showed the specific production rate that reached almost
the highest reported for antibody protein (45 pg/cell/
day). Furthermore, we have found several novel ways
that further improve the protein production level. For
example, the combination of the IR/MAR and the
DHFR/MTx technologies synergistically work and far
more rapidly and easily generate the cells of higher pro-
duction rate than previously.
In conclusion, the IR/MAR technology is a novel
highly-competitive technology for use in recombinant
protein production, and it further has potentials for
improvement.
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Figure 1 The IR/MAR plasmid can generates DMs (A), HSR (B), Ladder-HSR (C), and Fine ladder-HSR (D). Among the metaphase chromosome
spread, we detected the plasmid sequence by FISH in green. Gene expression was generally higher from DMs than HSR. However, DMs are
usually hard to be generated in CHO cells. The IR/MAR plasmid can efficiently generate the ladder and the fine ladder structure that is active in
transcription.
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